For people living with cancer, the triumph of early detection and treatment can be measured in hours rather than days. However, a group of scientists have addressed a critical hindrance to CD7+ T-cell therapy—their study reveals how the blood and lymph system actually responds to cancer and helps safe and effective treatment.
A paper describing this work, published today in Cell Reports, addresses a long-standing and significant challenge in treating cancers, says Tatyana Ustiska, the Jak-Peter Toyczko Professor of Human Lymphatic Systems, Computer Science and Engineering in the Department of Medicine at the University of Tennessee Health Science Center.
“The spectrum of symptoms for which CD7+ T cell therapies have been successful is heterogeneous, ” said the paper’s first author, Marius Wicht, PhD, a research investigator in the Ustiska lab at UVA Health, part of Knoxville. “CD7+ T cell therapy shows a lot of promise in cancer immunotherapy, but our approach has not progressed in a consistent manner. The CD8+ T cells that have been used for post-translational treatments have achieved promising clinical responses that demonstrated the effectiveness of both approaches. However, these treatments can slow the disease progression of CD8+ T cells that are infected by lymphoma in our disease model. “
But despite progress made in recent years, little progress has been made in promoting CD8+ T cell receptor candidates that are currently available for routine use as part of current CD7+ T cell therapy regimens. Recent studies reported that cells located in immune-compromised patients respond to CD9+ T cells that are injected subcutaneously throughout the body. These data released in support of the new paper from the U. S. National Library of Medicine highlight a potential new application of these T cell markers for cancer treatment. The paper analyzes cortical T-cell ambient light exposure, skin absorption by the skin and removal of light-emitting diodes via artificial skin grafts. It also expands on the performance of other CD8+ T cells and indicates that differential responses may be generated by non-tumor agents, in addition to or instead of standard CD7+ cell-based immunotherapy regimens, in order to improve the efficacy of noncancer therapeutic agents.
“Our work shows that responses to CD9+ T cells respond to cancer by halting tumor growth, ” Wicht said. “We also find special immune cells within the skin and neighboring organs light up and thus cause increased tissue perfusion, the ability of tissues to efficiently provide and accommodate lipolytic therapies (broad-spectrum treatments that activate lipolytic cells and thus prevent tumor growth and metastasis), and that our results are in alignment with previous neuroimaging data and other physiological effects of injury or trauma that are affected by the immune system. “
Blood and lymph system activation as the immune system responds.
Blood and lymph system involvement is the first step in CD8+ T cell therapy. The effects of immune activation or inflammation are supplemented by cold and heat exposure, while preclinical screening also reveals exposure to environmental toxins in the skin.
“If the immune system is activated in these conditions, it can promote differentiation or maintenance of CD8+ T cells in an immune-compromised individual, ” the paper outlines. “In this regard, it is a promising strategy because it is more practical to treat the patient at home. It takes less time, saves weight and can be more easily and cost-effectively carried out during the patient’s mobile and ever-changing environment. Allowing our CD8+ cells to actively respond to the treatment may make it more feasible to treat cancer at home. “
Cell therapies offer hope for a cure.
“We already show that CD8+ T cells respond in an inflammatory and pro-tumor erythrombiologic manner, and this underlines the potential of cell therapies outside of the body to treat cancer, ” Wicht said. “Our laboratory study suggests CD8+ T cells activate the anti-tumoral immune role in karyotypic and modeling experiments. Our data also provide new mechanistic insights to enable us to predict the response to CD8+ therapy using complex mathematical models and the mathematical modeling system Prof. Ivan Suvorin’s modular and integrated brain network model. We expect that this model could help us develop better strategies to evaluate the efficacy of cell therapies for treating cancer and improving cancer therapy. “
This work may also contribute to the development of cytotoxic agents that appear to be effective in cancer.
“Although it is still a long way from a cure, we hope that our study providing useful information on the viable strategies to enhance the response to CD8+ T cell-based immunotherapies will significantly advance the field of cancer immunotherapy, ” said the paper’s senior author, Akiko Okano,